bicyclo[3.2.2]nonane-1,5-dicarboxylic acid | 46368-93-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: bicyclo[3.2.2]nonane-1,5-dicarboxylic acid
• 英文别名: Bicyclo[3.2.2]nonane-1,5-dicarboxylic acid
• CAS: 46368-93-8
• 化学式: C₁₁H₁₆O₄
• 分子量: 212.246
• InChiKey: LVQWSNJMAGOMIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  bicyclo[3.2.2]nonane-1,5-dicarboxylic acid 在 N-溴代丁二酰亚胺(NBS) 、 五氯化磷 、 氨 、 potassium carbonate 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 异丙醇 、 乙腈 为溶剂， 反应 21.5h， 生成 ethyl 5-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)bicyclo[3.2.2]nonane-1-carboxylate
  参考文献：
  名称：

  [EN] BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS
  [FR] COMPOSÉS BENZAMIDES ET IMIDAZOPYRAZINES UTILISÉS COMME INHIBITEURS DE LA BTK

  摘要：

  提供的是根据式I的布鲁顿酪氨酸激酶（Btk）抑制剂化合物、其药学上可接受的盐、含有它们的药物组合物或其在治疗中的用途。

  公开号：

  WO2016106623A1
• 作为产物：
  描述：

  6,8-dioxo-bicyclo[3.2.2]nonane-1,5-dicarboxylic acid diethyl ester 在 盐酸 、 amalgamated zinc 、 甲苯 作用下， 生成 bicyclo[3.2.2]nonane-1,5-dicarboxylic acid
  参考文献：
  名称：

  High mountain psychro-xerophilous calcicolous pastures of the Iberian Peninsula:Minuartio-Poion ligulatae

  摘要：

  A syntaxonomical review of the Minuartio-Poion ligulatae (Festuco hystricis-Ononidetea striatae) in the Iberian Peninsula, supported by numerical classification (complete linkage clustering) and ordination (correspondence analysis), is presented. Communities of psychro-xerophilous calcicolous plants occur in the high mountains and "parameras" of the south and central western Iberian Peninsula, areas which suffer from severe frosts. The data collected point to three large groups of communities: those of the chorological Carpetano-lberico-Leonesa Province; those of the Castellano-Maestrazgo-Manchega Province; and those of the Mica Province. Within the latter group, similarities and differences between the communities were analyzed and two new associations (Herniario boissieri-Festucetum hystricis and Pimpinello gracilis-Festucetum nevadensis) were described. In addition, data clearly support the existence of a humidity-xericity gradient responsible for the distinction of the communities into different syntaxonomic units.

  DOI：

  10.1007/bf02899986

文献信息

• [EN] TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS<br/>[FR] INHIBITEURS DE LA BTK COMPRENANT UNE IMIDAZOPYRAZINE D'ALCOOL TERTIAIRE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016106624A1

  公开（公告）日：2016-07-07

  Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, or their use in therapy.

  根据公式（I），提供了Bruton酪氨酸激酶（Btk）抑制剂化合物，其药用盐，药物组合物或其在治疗中的用途。
• Benzamide imidazopyrazine Btk inhibitors
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10087188B2

  公开（公告）日：2018-10-02

  The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.

  本发明提供了根据式（I）的布鲁顿酪氨酸激酶（Btk）抑制剂化合物或其药学上可接受的盐，或包含这些化合物的药物组合物及其在治疗中的用途。特别是，本发明涉及式（I）的 Btk 抑制剂化合物在治疗 Btk 介导的疾病中的用途。
• Tertiary alcohol imidazopyrazine BTK inhibitors
  申请人：Liu Jian

  公开号：US10208047B2

  公开（公告）日：2019-02-19

  The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, Formula I or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.

  本发明提供了根据式I的布鲁顿酪氨酸激酶（Btk）抑制剂化合物，或其药学上可接受的盐，式I或包含这些化合物的药物组合物，以及它们在治疗中的用途。特别是，本发明涉及式 I 的 Btk 抑制剂化合物在治疗 Btk 介导的疾病中的用途。
• Assay for vapor condensates
  申请人：Essenlix Corporation

  公开号：US11523752B2

  公开（公告）日：2022-12-13

  The present invention relates to provide, among other things, the methods, devices, and systems that can simply and quickly collecting and analyzing a tiny amount of vapor condensates (e.g. exhaled breath condensate (EBC)).

  本发明主要涉及提供能够简单快速地收集和分析微量蒸汽冷凝物（如呼出气体冷凝物（EBC））的方法、装置和系统。
• TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3240546A1

  公开（公告）日：2017-11-08